Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Ascletis' NDA for second HCV therapy accepted in China, company begins trading in Hong Kong

Elizabeth S. Eaton
August 3, 2018 5:37 PM UTC

Ascletis Pharma Inc. (HKSE:1672) said China's State Drug Administration accepted its NDA for HCV therapy ravidasvir, a second-generation HCV NS5A protein inhibitor.

In June, Ascletis launched HCV drug Ganovo danoprevir in China. Ascletis has rights to the HCV NS3/4A protease inhibitor from Roche (SIX:ROG; OTCQX:RHHBY) in China, Hong Kong, Macau and Taiwan...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Ascletis Pharma Inc.